肿瘤标志物CA19-9和CA242联合检测在胆管癌中的诊断价值

目的研究多肿瘤标志物蛋白质芯片联合检测CA19-9和CA242在胆管癌中的应用。方法应用多肿瘤标志物蛋白质芯片诊断系统检测75例胆管疾病患者，经术中和(或)术后病理学证实，其中胆管癌40例、胆管良性病变35例。检测两种肿瘤标志物糖类抗原19—9(CA19-9)．糖类抗原242(CA242)的改变。结果75例患者中，糖类抗原199和糖类抗原242同时阳性者39例，其中胆管癌患者33例，其中糖类抗原19—9大于500u／ml者28例；胆管良性病变中，有6例为糖类抗原19—9和糖类抗原242同时阳性，一例糖类抗原19—9大于500u／ml者。当糖类抗原19—9和糖类抗原242同时阳性时，诊断胆管癌敏感性为82．5％，特异性为82．9％。结论应用多肿瘤标志物蛋白质芯片诊断系统检测胆管癌，当糖类抗原19—9和糖类抗原242同时阳性时，敏感性和特异性均较好，可作为临床诊断胆管癌的较好指标。

ROLE OF COMBINED TESING OF SERUM TUMOUR MAUKERS CA19-9 AND CA242 IN THE DIAGONSIS OF CHOLANCIGIOCARCINOMA

Objective To study the application of tumor markers protein chip in examining CA_(19-9) and CA_(242) in carcinoma of bile duct. Methods Examining the value of two tumor markers including CA_(19-9),,CA_(242) to the blood sample of 75 3cases of disease of bile duct .There were 40 cases of cholangiocarcinoma and 35 cases of benign pathological changes of bile duct by pathological diagnosis.Result 39 were positive in CA_(19-9) and CA_(242) in all cases, 33 were positive in CA_(19-9) and CA_(242) in 40 cases of cholangiocarcinoma while only 6 in 35 of benign pathological changes of bile duct. 28 were CA_(19-9)>500 U/ml in the former while 1 case in the latter. Sensitivity 82.5% .Speciality 82.9%.Conclusion CA_(19-9) and CA_(242) are good index to diagnose cholangiocarcinoma by tumor markers protein chip.